Biomea Fusion, Inc.
Biomea Fusion, Inc.
Your view on BMEA
Overview
What the company does, where it operates, and who runs it.
About Biomea Fusion, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Michael J. M. Hitchcock
- Headquarters
- 900 Middlefield Road, Redwood City, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Michael J. M. Hitchcock
- Headquarters
- 900 Middlefield Road, Redwood City, CA, US
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Infographics
Visual summary of the business at a glance.
Media
Videos and interviews covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks the stock is worth vs. the current price.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Comparables
List of peer companies in the same industry.
Institutional Ownership
Which funds and firms own the stock.
Insider Trading
Recent buying and selling by company executives.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
News
Latest headlines and market coverage.